Plain language summary of the MajesTEC-1 study of teclistamab for the treatment of people with relapsed or refractory multiple myeloma.
Future Oncol
; 19(12): 811-818, 2023 Apr.
Article
in En
| MEDLINE
| ID: mdl-37132225
Key words
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Multiple Myeloma
/
Antineoplastic Agents
Limits:
Humans
Language:
En
Journal:
Future Oncol
Year:
2023
Document type:
Article
Affiliation country:
Francia
Country of publication:
Reino Unido